{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:29:59Z","timestamp":1790501399559,"version":"4.1.0"},"reference-count":25,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,5,23]],"date-time":"2017-05-23T00:00:00Z","timestamp":1495497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01\u2010HL\u2010089758"],"award-info":[{"award-number":["R01\u2010HL\u2010089758"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01\u2010HL\u2010089901"],"award-info":[{"award-number":["R01\u2010HL\u2010089901"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001844","name":"Scleroderma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare mycophenolate mofetil (MMF) with placebo for the treatment of systemic sclerosis (SSc)\u2013related interstitial lung disease (ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We included participants enrolled in the placebo arm of Scleroderma Lung Study (SLS) I and the MMF arm of SLS II. SLS I randomized participants to receive either oral cyclophosphamide (CYC) or placebo for 1 year, while SLS II randomized participants to receive either MMF for 2 years or oral CYC for 1 year followed by 1 year of placebo. Eligibility criteria for SLS I and SLS II were nearly identical. The primary outcome was % predicted forced vital capacity (FVC), and key secondary outcomes included % predicted diffusing capacity for carbon monoxide (DL\n                      <jats:sc>co<\/jats:sc>\n                      ), the modified Rodnan skin thickness score (MRSS), and dyspnea. Joint models were created to evaluate the treatment effect on the course of these outcomes over 2 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At baseline, the MMF\u2010treated group in SLS II (n\u2009=\u200969) and the placebo\u2010treated group in SLS I (n\u2009=\u200979) had similar percentages of men and women and similar disease duration, SSc subtype, extent of skin disease, and % predicted FVC. MMF\u2010treated patients in SLS II were slightly older (mean\u2009\u00b1\u2009SD age 52.6\u2009\u00b1\u20099.7 years versus 48.1\u2009\u00b1\u200912.4 years;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0152) and had higher % predicted DL\n                      <jats:sc>co<\/jats:sc>\n                      (mean\u2009\u00b1\u2009SD 54.0\u2009\u00b1\u200911.1 versus 46.2\u2009\u00b1\u200913.3;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0002) than placebo\u2010treated patients in SLS I. After adjustment for baseline disease severity, treatment with MMF in comparison with placebo was associated with improved % predicted FVC (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), % predicted DL\n                      <jats:sc>co<\/jats:sc>\n                      (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), MRSS (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001), and dyspnea (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0112) over 2 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although there are inherent limitations in comparing participants from different trials, treatment with MMF was associated with improvements in physiologic outcomes and dyspnea compared with placebo, even after accounting for baseline disease severity. These results further substantiate the use of MMF for the treatment of SSc\u2010related ILD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.40114","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T13:13:10Z","timestamp":1491397990000},"page":"1451-1460","source":"Crossref","is-referenced-by-count":133,"title":["Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis\u2013Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II"],"prefix":"10.1002","volume":"69","author":[{"given":"Elizabeth R.","family":"Volkmann","sequence":"first","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Tashkin","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Roth","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna\u2010Maria","family":"Hoffmann\u2010Vold","sequence":"additional","affiliation":[{"name":"Oslo University Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kim","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Goldin","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Clements","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Elashoff","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker269"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.114264"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201606-426FR"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel244"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep295"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2861"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1823-1"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0012-3692(15)50949-5"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2007.07.021"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121043"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2014.08.002"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.6.751"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1081\/COPD-120030829"},{"key":"e_1_2_7_19_1","first-page":"1892","article-title":"Skin thickness score in systemic sclerosis (SSc): an assessment of inter\u2010observer variability in three independent studies","volume":"20","author":"Clements PJ","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0108"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2008.03.011"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4507"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2007.00952.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep284"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370904"},{"key":"e_1_2_7_26_1","first-page":"129","volume-title":"Systemic sclerosis","author":"Clements PJ","year":"2004"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.40114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.40114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:04:09Z","timestamp":1759932249000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.40114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,23]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1002\/art.40114"],"URL":"https:\/\/doi.org\/10.1002\/art.40114","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727475450.793584735","asserted-by":"object"}]},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,23]]}}}